Review article · 2026 · Open access
T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives
Frontiers in Immunology, 17, 1755512 · Published 3 June 2026 · DOI 10.3389/fimmu.2026.1755512
In brief
“T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives” is a 2026 review article by Kaaviyaa Muthughavi and 3 co-authors, published in Frontiers in Immunology. OpenAlex counts 2 citations as of 18 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 2
- Most cited in
- 2026 (2)
- Field-weighted impact
- 1.11
- References
- 143
- Authors
- 4
Abstract
T-cell engagers (TCEs) are a rapidly evolving class of cancer immunotherapies that redirect cytotoxic T cells to tumor-associated antigens independently of MHC presentation. This review outlines the development, structural formats, and therapeutic potential of various TCE platforms, including bispecific (BiTEs) and trispecific T-cell engagers (TriTEs), dual affinity re-targeting (DART), and other emerging formats. We also highlight the clinical success in treating hematologic malignancies as demonstrated by agents such as blinatumomab and teclistamab. We also discussed the ongoing challenges in solid tumors, such as antigen heterogeneity and the immunosuppressive tumor microenvironment. A comparative analysis with CAR-T cell therapies is provided, with a focus on efficacy, safety, toxicity, resistance, and cost. Strategies to increase specificity and reduce toxicity, such as tumor-selective activation (e.g., XPATs), CD3 affinity tuning, and multifunctional constructs, are discussed. Future directions include AI-driven design, synthetic biology, and potential applications beyond oncology, including autoimmune and infectious diseases. As scalable, off-the-shelf therapeutics, T-cell engagers are poised to become essential tools in personalized and accessible cancer treatment.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026). T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. Frontiers in Immunology, 17, 1755512. https://doi.org/10.3389/fimmu.2026.1755512
MLA 9
Muthughavi, Kaaviyaa, et al. “T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives.” Frontiers in Immunology, vol. 17, 2026, p. 1755512. https://doi.org/10.3389/fimmu.2026.1755512.
Chicago
Muthughavi, Kaaviyaa, Manoj Khokhar, Hem Chandra Jha, and Rajan Kumar Pandey. 2026. “T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives.” Frontiers in Immunology 17: 1755512. https://doi.org/10.3389/fimmu.2026.1755512.
Harvard
Muthughavi, K. et al. (2026) ‘T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives’, Frontiers in Immunology, 17, p. 1755512. doi:10.3389/fimmu.2026.1755512.
IEEE
K. Muthughavi, M. Khokhar, H. C. Jha, and R. K. Pandey, “T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives,” Frontiers in Immunology, vol. 17, p. 1755512, 2026, doi: 10.3389/fimmu.2026.1755512.
BibTeX
@article{muthughavi2026cell,
title = {{T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives}},
author = {Muthughavi, Kaaviyaa and Khokhar, Manoj and Jha, Hem Chandra and Pandey, Rajan Kumar},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
pages = {1755512},
doi = {10.3389/fimmu.2026.1755512},
url = {https://doi.org/10.3389/fimmu.2026.1755512}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- T-cell engagers
- bispecific T-cell engagers
- trispecific T cell engager
- blinatumomab
- teclistamab
- hematologic malignancies
- solid tumors
- immunosuppressive tumor microenvironment
Work with this paper
Most-cited papers in Immunology and Microbiology
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Ulrich K. Laemmli · Nature · 1970 · 249,784 citations
- Atherosclerosis — An Inflammatory DiseaseRussell Ross · New England Journal of Medicine · 1999 · 21,957 citations
- Continuous cultures of fused cells secreting antibody of predefined specificityGeorges Köhler, César Milstein · Nature · 1975 · 17,450 citations
- Inflammation and cancerLisa M. Coussens, Zena Werb · Nature · 2002 · 15,462 citations
- Dendritic cells and the control of immunityJacques Banchereau, Ralph M. Steinman · Nature · 1998 · 14,526 citations
Questions about this paper
How do I cite this paper in APA style?
Muthughavi, K., Khokhar, M., Jha, H. C., & Pandey, R. K. (2026). T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. Frontiers in Immunology, 17, 1755512. https://doi.org/10.3389/fimmu.2026.1755512
How many times has this paper been cited?
2 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Kaaviyaa Muthughavi, Manoj Khokhar, Hem Chandra Jha, Rajan Kumar Pandey.
What is the DOI of this paper?
10.3389/fimmu.2026.1755512, permanently at https://doi.org/10.3389/fimmu.2026.1755512. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.